Related Experiment Video

Updated: Oct 2, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Association between Serum Adipocyte Fatty Acid Binding Protein Level and Endothelial Dysfunction in Chronic

Hsin-Jou Fan1, Chih-Hsien Wang1,2, Bang-Gee Hsu1,2

  • 1Divisions of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.

Life (Basel, Switzerland)
|February 25, 2022
PubMed

Insights

Adipocyte fatty acid binding protein (A-FABP) is linked to endothelial dysfunction in hemodialysis patients. Higher A-FABP levels correlate with poorer vascular reactivity, indicating increased cardiovascular risk.

Area of Science:

  • Cardiovascular Science
  • Nephrology
  • Biochemistry

Background:

  • Endothelial dysfunction contributes to adverse cardiovascular outcomes in hemodialysis (HD) patients.
  • Adipocyte fatty acid binding protein (A-FABP) is implicated in atherosclerosis, a key factor in cardiovascular disease.

Purpose of the Study:

  • To investigate the relationship between serum A-FABP levels and endothelial function in patients undergoing chronic hemodialysis.
  • To determine if A-FABP is a potential biomarker for endothelial dysfunction in this population.

Main Methods:

  • Serum A-FABP levels were measured in 90 HD patients using enzyme immunoassay.
  • Endothelial function was assessed via digital thermal monitoring, calculating the vascular reactivity index (VRI).
  • Multivariate linear regression analyzed correlations between A-FABP, VRI, and clinical parameters.

Main Results:

  • 15.6% of HD patients exhibited poor vascular reactivity (VRI < 1.0).
  • Patients with poor VRI had significantly higher serum A-FABP levels (p=0.001).
  • Multivariate analysis revealed a negative correlation between log-VRI and serum A-FABP levels.

Conclusions:

  • Serum A-FABP levels are significantly correlated with endothelial dysfunction in chronic hemodialysis patients.
  • A-FABP may serve as a potential biomarker for assessing cardiovascular risk associated with endothelial dysfunction in HD patients.

Keywords:
adipocyte fatty acid binding proteinendothelial dysfunctionhemodialysisvascular reactivity index

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

2.3K

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
134
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
250
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
376
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
169
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
95
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
129